REVIEW PAPER
Productivity loss as a result of rheumatic diseases – absenteeism and presenteeism
Submission date: 2013-08-08
Final revision date: 2013-10-02
Acceptance date: 2013-10-08
Online publication date: 2013-10-31
Publication date: 2013-10-30
Reumatologia 2013;51(5):355-362
KEYWORDS
TOPICS
ABSTRACT
Rheumatic diseases affect not only patient’s health, but also their life and work. The study results show that these conditions not only increase absenteeism (being absent from work), but also presenteeism (being present at work but working at reduced capacity) which result in an overall productivity loss. Between 32% to 50% of patients with RA cease their work after 10 years from the first symptoms of the disease. It is estimated that presenteeism and absenteeism caused by RA generates a loss of 3.2 and 0.2 absenteeism day for every 20 days, respectively.
Studies on productivity loss are based mainly on questionnaire tools. In rheumatic diseases most commonly used instruments are: Rheumatoid Arthritis Specific Work Productivity Survey (WPS-RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA-WIS), Work Limitations Questionnaire (WLQ) and the Work Productivity and Activity Impairment (WPAI).
Studies on productivity loss are based mainly on questionnaire tools. In rheumatic diseases most commonly used instruments are: Rheumatoid Arthritis Specific Work Productivity Survey (WPS-RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA-WIS), Work Limitations Questionnaire (WLQ) and the Work Productivity and Activity Impairment (WPAI).
REFERENCES (40)
1.
Zheltoukhova K, Bevan S, Reich A. Zdolni do pracy? Choroby układu mięśniowo-szkieletowego a rynek pracy w Polsce. The Work Fundation, London 2011; 24.
2.
Koehne N, Lednicki B, Piekarzewska M i wsp. Stan zdrowia ludności Polski w 2009 roku. Główny Urząd Statystyczny, Warszawa 2011. .
3.
Łabęcka M, Kania A. Orzeczenia lekarzy orzeczników ZUS o niezdolności do pracy wydane w 2012 roku. Zakład Ubezpieczeń Społecznych, Warszawa 2013.
4.
Karczewicz E, Łabęcka M. Wydatki na świadczenia z ubezpieczeń społecznych związane z niezdolnością do pracy. Zakład Ubezpieczeń Społecznych, Warszawa 2011.
5.
Jędryka-Góral A, Łastowiecka E, Bugajska J. Jakość życia w chorobach reumatycznych a praca zawodowa. Reumatologia 2004; 42: 458-466.
6.
Wisłowska M, Kanecki K, Tyszko P, Kapała A. Jakość życia zależna od zdrowia u pacjentów z reumatoidalnym zapaleniem stawów. Reumatologia 2010; 48: 104-111.
7.
Sierakowska M, Sierakowski S, Wróblewska M, Krajewska-Kułak E. Problemy zdrowotne pacjentów z chorobą zwyrodnieniową stawów i ich wpływ na jakość życia uwarunkowaną stanem zdrowia. Reumatologia 2010; 48: 372-379.
8.
Wysocka-Skurska I, Sierakowska M, Sierakowski S. Ocena jakości życia pacjentów z reumatoidalnym zapaleniem stawów w zależności od stosowanej terapii farmakologicznej. Reumatologia 2012; 50: 16-23.
9.
Słowińska I, Małdyk P. Losy chorych na reumatoidalne zapalenie stawów leczonych metodą endoprotezoplastyki w obrębie stawów kończyn dolnych. Reumatologia 2012; 50: 403-409.
10.
Kowalczyk K, Głuszko P. Ocena jakości życia chorych na reumatoidalne zapalenie stawów za pomocą badań ankietowych. Reumatologia 2009; 47: 4-9.
11.
Bączyk G. Przegląd badań nad jakością życia chorych na reumatoidalne zapalenie stawów. Reumatologia 2008; 46: 372-379.
12.
Koligat D, Leszczyński P, Pawlak-Buś K i wsp. Ocena jakości życia pacjentów z reumatoidalnym zapaleniem stawów leczonych leflunomidem – przegląd literatury. Reumatologia 2012; 50: 227-232.
13.
Bansback N, Zhang W, Walsh D, et al. Factors associated with absenteeism, presenteeism and activity impairment in patients in the. Rheumatology 2012; 51: 375-384.
14.
Boles M, Pelletier B, Lynch W. The relationship between health risks and work productivity. J Occup Environ Med 2004; 46: 737-745.
15.
Zhang W, Bansback N, Boonen A, et al. Development of a composite questionnaire, the valuation of lost productivity, to value productivity losses: application in rheumatoid arthritis. Value Health 2012; 15: 46-54.
16.
Escorpizo R, Bombardier C, Boonen A, et al. Worker productivity outcome measures in arthritis. J Rheumatol 2007; 34: 1372-1380.
17.
Anis A, Zhang W, Emery P, et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology 2009; 48: 1283-1289.
18.
Ardito C, d’Errico A, Leombruni R, et al. Health and well-being at work: A report based on the fifth European Working Conditions. Eurofound, Dublin 2012.
19.
Karczewicz E, Sikora A. Absencja chorobowa w 2012 roku. Zakład Ubezpieczeń Społecznych, Warszawa 2013.
20.
Malińska M. Prezenteizm – zjawisko nieefektywnej obecności w pracy. Instytut Medycyny Pracy im. prof. J. Nofera w Łodzi. Medycyna Pracy 2013; 64 (3). http://medpr.imp.lodz.pl.
22.
Pauly MV, Nicholson S, Polsky D, et al. Valuing reductions in on-the-job illness: 'presenteeism' from managerial and economic perspectives. Health Econ 2008; 17: 469-485.
23.
Tang K, Beaton DE, Boonen A, et al. Measures of work disability and productivity: Rheumatoid Arthritis Specific Work Productivity Survey (WPS-RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA-WIS), Work Limitations Questionnaire (WLQ). Arthritis Care Res 2011; 63 Suppl: S337-349.
24.
Prasad M, Wahlqvist P, Shikiar R, et al. A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective. Pharmacoeconomics 2004; 22: 225-244.
25.
Mattke S, Balakrishnan A, Bergamo G, et al. A review of methods to measure health-related productivity loss. Am J Manag Care 2007; 13: 211-217.
26.
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 5: 353-365.
27.
Reilly Associates. [Online] [Zacytowano: 28. 07. 2013]. Dostępne na: http://www.reillyassociates.ne....
28.
Filipowicz-Sosnowska A, Rupiński R. Złożoność procesu niepełnosprawności u chorych na reumatoidalne zapalenie stawów. Reumatologia 2005; 43: 138-146.
29.
Lenssinck ML, Burdorf A, Boonen A, et al. Consequences of inflammatory arthritis for workplace productivity loss and sick leave: a systematic review. Ann Rheum Dis 2013; 72: 493-505.
30.
Burton W, Morrison A, Maclean R, et al. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond) 2006; 56: 18-27.
31.
Beaton D, Bombardier C, Escorpizo R, et al. Measuring worker productivity: frameworks and measures. J Rheumatol 2009; 36: 2100-2109.
32.
Beaton DE, Tang K, Gignac MA, et al. Reliability, validity, and responsiveness of five at-work productivity measures in patients with rheumatoid arthritis or osteoarthritis. Arthritis Care Res (Hoboken) 2010; 62: 28-37.
33.
Zhang W, Bansback N, Kopec J, Anis AH. Measuring time input loss among patients with rheumatoid arthritis: validity and reliability of the Valuation of Lost Productivity questionnaire. J Occup Environ Med 2011; 53: 530-536.
34.
Merkesdal S, Ruof J, Schöffski O, et al. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001; 44: 528-534.
35.
ter Wee MM, Lems WF, Usan H, et al. The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review. Ann Rheum Dis 2012; 71: 161-171.
36.
Pavelka K, Szekanecz Z, Damjanov N, et al. Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. Clin Rheumatol 2013; 32: 1275-1281.
37.
Her M, Kavanaugh A. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis. Clin Exp Rheumatol 2012; 73 (Suppl): S107-S111.
38.
Braakman-Jansen LM, Taal E, Kuper IH, van de Laar MA. Productivity loss due to absenteeism and presenteeism by different instruments in patients with RA and subjects without RA. Rheumatology (Oxford) 2012; 51: 354-361.
39.
Brooks A, Hagen SE, Sathyanarayanan S, et al. Presenteeism: critical issues. J Occup Environ Med 2010; 52: 1055-1067.
40.
Wiland P, Świerkot J, Maśliński W. Certolizumab pegol w leczeniu reumatoidalnego zapalenia stawów. Reumatologia 2011; 49: 253-263.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
